Clinical Trial Update: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection [Phase 1]

View source ↗

Summary

A terminated Phase 1 clinical trial evaluated ibrutinib for relapsed or refractory B-cell non-Hodgkin lymphoma in adults with HIV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• HIV Infection

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Status: TERMINATED